EnSidNet: Enhanced Hybrid Siamese-Deep Network for grouping clinical trials into drug-development pathways
Abstract
Siamese Neural Networks have been widely used to perform similarity classification in multi-class settings. Their architecture can be used to group the clinical trials belonging to the same drug-development pathway along the several clinical trial phases. Here we present an approach for the unmet need of drug-development pathway reconstruction, based on an Enhanced hybrid Siamese-Deep Neural Network (EnSidNet). The proposed model demonstrates significant improvement above baselines in a 1-shot evaluation setting and in a classical similarity setting. EnSidNet can be an essential tool in a semi-supervised learning environment: by selecting clinical trials highly likely to belong to the same drug-development pathway it is possible to speed up the labelling process of human experts, allowing the check of a consistent volume of data, further used in the model’s training dataset.
BibTeX
@inproceedings{pagani-2021-ensidnet,
title = "{E}n{S}id{N}et: Enhanced Hybrid {S}iamese-Deep Network for grouping clinical trials into drug-development pathways",
author = "Pagani, Lucia",
editor = "Toutanova, Kristina and
Rumshisky, Anna and
Zettlemoyer, Luke and
Hakkani-Tur, Dilek and
Beltagy, Iz and
Bethard, Steven and
Cotterell, Ryan and
Chakraborty, Tanmoy and
Zhou, Yichao",
booktitle = "Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies",
month = jun,
year = "2021",
address = "Online",
publisher = "Association for Computational Linguistics",
url = "https://aclanthology.org/2021.naacl-main.24/",
doi = "10.18653/v1/2021.naacl-main.24",
pages = "254--266"
}